These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32900789)

  • 1. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
    Kulkarni AA; Ebadi M; Zhang S; Meybodi MA; Ali AM; DeFor T; Shanley R; Weisdorf D; Ryan C; Vasu S; Rashidi A; Patel MR
    ESMO Open; 2020 Sep; 5(5):e000803. PubMed ID: 32900789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
    Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
    Nyein AF; Bari S; Hogue S; Zhao Y; Maller B; Sha S; Gomez MF; Rollison DE; Robinson LA
    BMC Cancer; 2022 Jan; 22(1):101. PubMed ID: 35073876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
    Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
    J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Cortellini A; Ricciuti B; Facchinetti F; Alessi JVM; Venkatraman D; Dall'Olio FG; Cravero P; Vaz VR; Ottaviani D; Majem M; Piedra A; Sullivan I; Lee KA; Lamberti G; Hussain N; Clark J; Bolina A; Barba A; Benitez JC; Gorría T; Mezquita L; Hoton D; Aboubakar Nana F; Besse B; Awad MM; Pinato DJ
    Ann Oncol; 2021 Nov; 32(11):1391-1399. PubMed ID: 34400292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
    Chambers LM; Michener CM; Rose PG; Reizes O; Yao M; Vargas R
    Gynecol Oncol; 2021 Apr; 161(1):211-220. PubMed ID: 33504455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.
    Metselaar-Albers M; Meijerman I; Engels F; Haanen J; Beijnen J; Lalmohamed A
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
    Tamura K; Okuma Y; Nomura S; Fukuda A; Masuda K; Matsumoto Y; Shinno Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):216. PubMed ID: 38668936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
    Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
    Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Galli G; Triulzi T; Proto C; Signorelli D; Imbimbo M; Poggi M; Fucà G; Ganzinelli M; Vitali M; Palmieri D; Tessari A; de Braud F; Garassino MC; Colombo MP; Lo Russo G
    Lung Cancer; 2019 Jun; 132():72-78. PubMed ID: 31097097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
    Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
    Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
    Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
    Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
    Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.